IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

PURPOSE: Irosustat is a first-generation, orally active, irreversible steroid sulfatase inhibitor. We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Palmieri, Carlo, Stein, Rob C., Liu, Xinxue, Hudson, Emma, Nicholas, Hanna, Sasano, Hironobu, Guestini, Fouzia, Holcombe, Chris, Barrett, Sophie, Kenny, Laura, Reed, Sadie, Lim, Adrian, Hayward, Larry, Howell, Sacha, Coombes, R. Charles
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2017
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5543190/
https://ncbi.nlm.nih.gov/pubmed/28612226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4328-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados